Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912753 | 1.00 | EGFR (0.57) | EGFRPLAULCKKDRJAK3 | |
| Benzene SCHEMBL28800797 | 0.96 | EGFR (0.53) | EGFRPLAULCKKDRJAK3 | |
| SCHEMBL5494272 | 0.84 | LCK (0.58) | EGFRLCKKDRJAK3MAPK14 | |
| SCHEMBL24150165 | 0.83 | HTT (0.58) | EGFRPLAULCKKDRJAK3 | |
| SCHEMBL5488838 | 0.80 | MAP4K4 (0.61) | LCKKDRJAK3MAPK14KDM4E | |
| SCHEMBL2130969 | 0.79 | PIK3CG (0.53) | LCKKDRJAK3MAPK14DYRK1A | |
| SCHEMBL3481303 | 0.79 | KDM4E (0.55) | EGFRPLAULCKKDRJAK3 | |
| SCHEMBL2632884 | 0.79 | LCK (0.57) | LCKKDRJAK3MAPK14DYRK1A | |
| SCHEMBL15679285 | 0.79 | LCK (0.49) | EGFRLCKKDRJAK3MAPK14 | |
| SCHEMBL31155594 | 0.79 | KDM4E (0.55) | EGFRPLAULCKKDRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118142359-A | Anti-pollution and oxidation-resistant reverse osmosis membrane with low-surface-energy coating and preparation method thereof | 万华化学集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120040904-A1 | Boronate Medicaments for Preventing Thrombosis During Surgery | Trigen Holdings AG (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20100113393-A1 | Boronic Acid Salts | PAION DEUTSCHLAND GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100036159-A1 | Peptide boronic acid inhibitors | PAION DEUTSCHLAND GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20080287370-A1 | Boronic Acid Salts Useful in Parenteral Formulations | PAION DEUTSCHLAND GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080234228-A1 | Peptide boronic acid drug; thrombosis therapy; anticoagulants | PAION DEUTSCHLAND GMBH (DE) | 2008-09-25 | — | — | US | disclosed |
| US-20080166396-A1 | Boronate Medicaments Suitable for Short Duration Anticoagulation | TRIGEN HOLDINGS AG CLAREVILLE HOUSE (GB) | 2008-07-10 | — | — | US | disclosed |
| US-20050176651-A1 | For inhibiting thrombin in the prophylaxis or therapy of disease; tripeptidie boronic acid is reacted with strong alkali or alklaline metal base to form metal salt in presence of acetonitrile, tetrahydrofuran or an alcohol solvent | TRIGEN LIMITED | 2005-08-11 | — | — | US | disclosed |
| EP-1561466-A2 | Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis | TRIGEN LIMITED (GB) | 2005-08-10 | — | — | EP | disclosed |
| US-20050119226-A1 | Methods for synthesizing organoboronic compounds and products thereof | TRIGEN LIMITED | 2005-06-02 | — | — | US | disclosed |
| EP-1466916-A1 | Peptide boronic acids useful in making salts thereof | TRIGEN LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| EP-1466917-A1 | Method for making peptide boronic acids and acids obtainable thereby | TRIGEN LIMITED (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-20040138175-A1 | Boronic acid salts useful in parenteral formulations | TRIGEN LIMITED | 2004-07-15 | — | — | US | disclosed |
| EP-1400245-A1 | Boronic acid salts useful in parenteral formulations for selective thrombin inhibition | TRIGEN LIMITED (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004022072-A1 | BORONIC ACID SALTS ANT THEIR USE IN THE TREATMENT OF THROMBOSIS | TRIGEN LIMITED (GB) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004022070-A1 | BORONIC ACID SALTS USEFUL IN PARENTERAL FORMULATIONS FOR SELECTIVE THROMBIN INHIBITION | TRIGEN LIMITED (GB) | 2004-03-18 | — | — | WO | disclosed |
| EP-1396270-A1 | Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis | TRIGEN LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040904-A1 | Boronate Medicaments for Preventing Thrombosis During Surgery | F9, FGB, TFPI | EGFR 1850/4885PLAU 740/4885LCK 2282/4885 |
| US-20100113393-A1 | Boronic Acid Salts | GCG, GRPR, BPGM | EGFR 235/4885PLAU 1754/4885LCK 3858/4885 |
| US-20080287370-A1 | Boronic Acid Salts Useful in Parenteral Formulations | HBZ, BPGM, GCG | EGFR 1117/4885PLAU 2341/4885LCK 3778/4885 |
| US-20040138175-A1 | Boronic acid salts useful in parenteral formulations | HBZ, BPGM, GCG | EGFR 1120/4885PLAU 2375/4885LCK 3808/4885 |
| US-20050176651-A1 | For inhibiting thrombin in the prophylaxis or therapy of disease; tripeptidie boronic acid is reacted with strong alkali or alklaline metal base to form metal salt in presence of acetonitrile, tetrahydrofuran or an alcohol solvent | DPP7, SERPINC1, RNPEP | EGFR 1041/4885PLAU 140/4885LCK 3658/4885 |
| US-20050119226-A1 | Methods for synthesizing organoboronic compounds and products thereof | BCHE, HMBS, APEH | EGFR 2246/4885PLAU 389/4885LCK 2204/4885 |
| US-20080166396-A1 | Boronate Medicaments Suitable for Short Duration Anticoagulation | F2, HABP2, BDKRB1 | EGFR 2383/4885PLAU 405/4885LCK 3888/4885 |
| US-20100036159-A1 | Peptide boronic acid inhibitors | BMX, YBX1, HAX1 | EGFR 69/4885PLAU 3737/4885LCK 612/4885 |
| US-20080234228-A1 | Peptide boronic acid drug; thrombosis therapy; anticoagulants | NPPA, BDKRB2, BCAT2 | EGFR 743/4885PLAU 181/4885LCK 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.